News | Cardiac Diagnostics | July 01, 2021

FDA Approves AngelMed Enhanced Real-Time Cardiac Monitor for Acute Coronary Syndrome (ACS) Events

AngelMed Guardian System prompts high-risk ACS patients to seek medical care

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device


July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation AngelMed Guardian device. It is the world's first implantable cardiac detection monitor and patient-warning system for acute coronary syndrome (ACS) events, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device.

The AngelMed Guardian device is implanted subcutaneously by a cardiologist during a low-risk, outpatient surgical procedure. Using a patented algorithm, the AngelMed Guardian continuously records the heart's electrical activity, 24 hours a day, monitoring for electrical changes that can indicate an impending ACS event. The AngelMed Guardian device provides a more effective diagnosis of a life-threatening condition when compared to patient symptoms alone.[1]

"Patients who have had a prior ACS event often remain at high-risk of a recurrent event. Even those patients who are on alert for another potential cardiac event may delay seeking treatment," said Michael Gibson M.D., Boston Clinical Research Institute. "The AngelMed Guardian System has demonstrated the ability to identify the earliest signs of an ACS event, including heart attacks, more effectively than patients' symptoms alone, and in patients who do not experience symptoms at all."

"The improved AngelMed Guardian device will have a meaningful effect on the current standard of patient cardiology care for ACS events. Our dedicated team and supporting physicians have worked tirelessly to bring this disruptive technology to market," said AngelMed Chief Executive Officer Brad Snow. "As the first real-time detection device for high-risk heart attack patients, the AngelMed Guardian System provides critical data at the point of care, along with peace of mind for physicians and patients alike."

"Our key learnings based on hundreds of thousands of hours of clinical monitoring data for many ambulatory patients with cardiovascular disease provides a technology platform for future offerings. Our patient-centric approach will drive our research and development," said Dave Keenan, AngelMed chief operating officer.

Every 40 seconds, someone in the U.S. suffers a myocardial infarction or heart attack.2 The most important risk factors for another cardiovascular event in post-heart attack patients are age, medical history, comorbidities, and the severity of their first ACS event.[3] Despite proactive ongoing efforts over the last decade from the medical community to better educate the public on signs and symptoms of a heart attack, the time from symptom onset to arrival at a hospital remains static at eight hours.[4]

For more information: www.angel-med.com

References:

1. U.S. Food and Drug Administration Website. Summary of Safety and Effectiveness Data. https://www.fda.gov/media/96475/download. Accessed May 6, 2021

2. Centers for Disease Control and Prevention. (2012, August). NCHS data brief: Prevalence of Uncontrolled Risk Factors for Cardiovascular Disease: United States, 1999–2010  (No. 109). Retrieved from https://www.cdc.gov/nchs/data/databriefs/db103.pdf.  

3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130(25):2354-2394. doi: 10.1161/CIR.0000000000000133. 

4. Holmes DR, Krucoff MW, Mullin C, et al. Implanted monitor alerting to reduce treatment delay in patients with acute coronary syndrome events. J Am Coll Cardiol. 2019;22:2047-2055. doi: 10.1016/j.jacc.2019.07.084.


Related Content

News | Cath Lab

March 14, 2023 — Royal Philips, a global leader in health technology, and the Gibraltar Health Authority, announced they ...

Home March 14, 2023
Home
News | Cath Lab

March 1, 2023 — SpectraWAVE, Inc., a medical imaging company focused on improving the treatment and outcomes for ...

Home March 01, 2023
Home
News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
Subscribe Now